BioSpace News Archive

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company’s Board of Directors and Chair of the Board’s Audit Committee.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced, following publication of promising data from a Phase 2b Dupuytren’s trial in the June 2022 issues of The Lancet Rheumatology, that 180 Life Sciences has initiated preliminary consultations with regulatory agencies in both the UK and USA, with the assistance of Kinexum, the Company’s regulatory advisor.

Green Scientific Labs Holdings Inc. (“Green Scientific Labs” or the “Company”), leading multi-state provider of innovative cannabis and hemp testing technologies and methods, has achieved International Organization for Standardization (ISO) ISO/IEC 17025 recertification in both its Florida and Arizona laboratories.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today updated results from its ongoing open-label Phase 1/2 study, which represents the longest duration of clinical observation for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A.

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) (“ FSD Pharma ” or the “ Company ”), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announces the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) and Health Canada detailing a planned Phase 2 clinical trial of FSD-PEA.

seqWell today announced a partnership with Element Biosciences Inc., developer of the Element AVITI™ System.

Apollo Endosurgery, Inc. announced highlights today from data presented at Digestive Disease Week May 21-24.

Embody, Inc., a privately-held medical device company focused on soft tissue healing, announced today that it has received 510(k) clearances from the Food and Drug Administration (FDA) for its TAPESTRY RC System for the treatment of rotator cuff disease.

Nanalysis Scientific Corp. releases its first quarter results ending March 31, 2022.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx Inc., and Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be presenting at the LD Micro Invitational XII which is being held on June 7– 9, 2022.